Quantcast
Last updated on April 23, 2014 at 20:01 EDT

Latest Thalidomide Stories

2011-12-12 12:50:55

Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego. The drug thalidomide achieved infamy in the early 1960s as the cause of severe birth defects after being given to pregnant mothers for...

2011-12-11 19:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma. The Prescription Drug User Fee Act (PDUFA) date for completion of review by the FDA of the NDA is July 27, 2012. In the NDA filing...

2011-12-10 20:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA. "This expanded data set supports our belief in the potential of carfilzomib to treat late-stage patients with...

2011-11-29 07:00:00

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submission for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. "The FDA's acceptance of the new drug application submission for carfilzomib marks an important milestone for bringing this...

2011-11-17 12:42:00

SEATTLE, Nov. 17, 2011 /PRNewswire/ -- Attorneys representing a group of U.S. citizens suffering from severe birth defects they believe were caused by the drug thalidomide have filed a lawsuit in federal court to compel the FDA to release records they believe will show the drug was widely distributed in the United States. The suit seeks to compel the FDA to respond to a number of Freedom of Information Act (FOIA) requests by attorneys representing the patients, some filed more than a...

2011-11-07 15:00:00

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011, at the San Diego Convention Center in San Diego, CA. "The results being presented at ASH demonstrate carfilzomib's potential activity along all lines of multiple myeloma, and we are...

2011-09-28 07:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has completed the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval process for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. In addition, Onyx has requested priority review of the application, which reduces...

2011-06-15 00:00:27

BioPlus Specialty Pharmacy, one of the nation's leading specialty pharmacies, offers numerous oncology drugs as well as an oncology therapy management program that increases patient compliance. Altamonte Springs, FL (PRWEB) June 13, 2011 BioPlus Specialty Pharmacy (BioPlus), one of the nation's leading specialty pharmacies, has numerous oral oncology medications available for patients with cancer. As a specialty pharmacy, BioPlus works with patients and their physicians in oncology...

2011-05-19 07:11:00

INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma. Results from the Phase I study will be presented on Sunday, June 5 at 11:30 a.m. CDT during the Lymphoma and Plasma Cell Disorders Oral Abstract Session (Abstract #8012) at the 47th Annual Meeting of the...

2011-04-19 14:29:26

New research in the FASEB Journal details the first evidence that breakdown products of thalidomide produce the specific, toxic effects of thalidomide in embryos Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects. This is important as thalidomide is still used to treat diseases like...